Compliance that outlasts the engagement.
BioCompliance Advisory traces audit findings to where they start — in the room as well as the record — and builds the quality system and internal team that keep a facility ready for certification. Evidence-based, standard-cited, and designed to make itself unnecessary at the facility level.
Why we exist, and where we're taking the industry.
Mission
To help pharmaceutical-grade crop producers worldwide achieve, maintain, and leverage international regulatory certification — building the internal quality infrastructure, trained teams, and institutional knowledge that turn compliance into a permanent competitive advantage.
Vision
A world in which every licensed medicinal cannabis facility — regardless of geography — operates to the same rigorous quality standard that protects patients, enables cross-border trade, and builds a sustainable industry. BioCompliance exists to close the gap between that standard and current operational reality.
How we operate, every engagement.
Technical Precision
No shortcuts on documentation, no inflated audit-readiness scores — precision over commercial convenience.
Peer-Level Engagement
Clients are technical operators, not buyers of a commodity service. We engage as equals.
Transfer of Capability
Every engagement ends with the client team owning their own quality system — not dependent on us.
Regulatory Candour
If a facility is not ready, BioCompliance says so before the audit, not after.
A structural gap is driving demand.
Importing markets are converging on certification as a condition of market access, while producing-country certification rates remain in the low single digits. Germany's MedCanG, Australia's July 2023 GACP-to-GMP mandate, and the UK's NHS expansion have triggered a first-certification wave among producers in Thailand, Colombia, and Israel.
Source: DTAM licence register; BfArM import statistics, 2025.
Twenty years in the grow room. Now the standard behind it.
Pato Stein ran commercial cultivation for more than twenty years before moving into GACP and EU-GMP compliance. Cultivation work spans five continents; today the practice is concentrated in Thailand and Southeast Asia, where certification is the bottleneck between a licensed farm and an export contract. Pato works in English and Spanish.
- 2026–27 Postgraduate Diploma, Pharmaceutical Quality Systems — IL3, Universitat de Barcelona (30 ECTS, in progress)
- 2025 ECA Academy — The GMP-Compliance Manager — two-day course, Vienna: CAPA, ICH Q9 risk analysis, product quality review, supplier qualification
- 2025 20th QP Forum, European QP Association — Barcelona
- 2025 GMP Pharma Congress (FDA GMP), ECA Foundation — Wiesbaden
- 20+ yrs Commercial cultivation — indoor, greenhouse, outdoor, coco, rockwool, hydro, aeroponic
- 13+ Countries, five continents — facilities visited across the United States (California, Colorado, Nevada, Washington, Maine), Colombia, Argentina, Chile, Spain, Portugal, the UK, Germany, Switzerland, Czechia, Morocco and South Africa, among others
- 25+ Cultivation sites in Thailand — the current centre of gravity for the practice, and a primary market rather than an afterthought
Independently operated. Built on Hydrofarm's 50+ years of expertise.
A Division of Hydrofarm
BioCompliance Advisory is an independently operated division of Hydrofarm, founded and led by Pato Stein and built on the cultivation-equipment and horticultural expertise Hydrofarm has developed over more than 50 years.
- Equipment documentation on request — if you already run Hydrofarm systems, their IQ/OQ/PQ documentation is available. No finding or programme ever depends on it.
- Deep agronomic pedigree — five decades of horticultural science behind every finding, not just a document review.
- Operates under Hydrofarm corporate governance, with a dedicated and independent management team.
- Founder-led, with direct access to the Hydrofarm technical and commercial network.
- Vendor-neutral by policy — Hydrofarm products are never a condition of any finding, corrective action or programme.
How We Contract
- Milestone-based client contracts, tied to programme stages — not flat invoicing.
- Explicit, written deliverable definitions per stage — no ambiguity about what's owed and when.
- IP ownership: custom deliverables transfer to the client on full payment; BioCompliance retains its methodology IP.
- Professional indemnity and public liability insurance in place from Day 1 of every engagement.
Book a 20-minute readiness call.
No charge, no pitch. You'll leave knowing which standard applies to you and roughly how far off you are.